Key clinical point: Twelve weeks of empagliflozin treatment of patients with heart failure led to a clinically meaningful drop in average pulmonary artery pressures.

Major finding: Pulmonary artery diastolic pressure fell by an average of 1.5 mm Hg, compared with control patients, after 12 weeks on treatment.

Study details: EMBRACE HF, a multicenter, randomized, controlled study that enrolled 65 patients.

Disclosures: EMBRACE HF was funded by Boehringer Ingelheim, the company that markets empagliflozin (Jardiance) along with Eli Lilly. Dr. Kosiborod has received research support and honoraria from Boehringer Ingelheim, and he has received honoraria from several other companies.